Eagle Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$449K Buy
858
+13
+2% +$6.66K 0.33% 61
2026
Q2
$420K Buy
845
+33
+4% +$14.6K 0.32% 69
2026
Q1
$363K Buy
812
+96
+13% +$44.8K 0.33% 65
2025
Q4
$325K Buy
+716
New +$309K 0.28% 67

Other funds holding VRTX

Eagle Wealth Advisors's VRTX Position: Q3 2026 in Review

Eagle Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q3 2026, buying an estimated $6.66K and bringing the position to 858 shares worth $449K. The position accounts for 0.33% of the portfolio, ranked #61.

Eagle Wealth Advisors first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Eagle Wealth Advisors held 858 shares of Vertex Pharmaceuticals worth $449K as of Q3 2026.
  • Eagle Wealth Advisors bought 13 Vertex Pharmaceuticals shares in Q3 2026, an estimated $6.66K.
  • Vertex Pharmaceuticals made up 0.33% of Eagle Wealth Advisors's portfolio in Q3 2026, its #61 holding.
  • Eagle Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Eagle Wealth Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.